Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

Matza, Louis S.; Boye, Kristina S.; Stewart, Katie D.; Coyne, Karin S.; Wullenweber, Paula; Cutts, Katelyn; Jordan, James O.; Wang, Qianqian; Yu, Maria; Currie, Brooke M.; Malley, Karen G.; Ishak, KJ; Hietpas, Ryan T.; García‐Pérez, Luis‐Emilio

doi:10.1111/dom.13902

Cited by 35 publications

(39 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, a significantly larger proportion of patients preferred the dulaglutide device (84.2%) over the semaglutide device (12.3%) in a cross-over trial of US patients with T2DM. 17 Similar results were also found in a vignette-based study of these devices among Italian patients, with 88.4% preferring the dulaglutide device over the semaglutide device (11.6%). 18 There is limited research on T2DM patient characteristics, HRQoL, and treatment preferences among patients with diabetes in the Middle East, and specifically, in KSA.…”

Section: Introductionsupporting

confidence: 73%

<p>Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia</p>

Gelhorn¹,

Boye²,

Shalhoub³

et al. 2020

PPA

View full text Add to dashboard Cite

Background The Kingdom of Saudi Arabia (KSA) has the second highest prevalence of type 2 diabetes mellitus (T2DM) in the Middle East. There is a paucity of research on the experiences and treatment preferences of patients with T2DM in KSA. This study explored Saudi patients’ health-related quality of life, eating habits, experiences during Ramadan, and preference between two glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment devices. Methods A cross-sectional, observational study was conducted in three cities in KSA. Participants completed sociodemographic and clinical forms, EQ-5D-5L, Impact of Weight on Self-Perceptions, and a diabetes treatment survey. Participants also viewed instructional videos on GLP-1 RA injection devices and indicated their device preference. Results Of the 310 participants, 53% were male. The mean age was 43 years (range: 30.0–75.0), duration since diabetes diagnosis was 6.3 years (range: 0.2–27.1), the most commonly reported last HbA1c level was between ≥7.1% and 8% (45%). The mean EQ-5D-5L index score was 0.90, with some participants reporting problems with pain/discomfort (34.5%) and usual activities (33.2%). Patients reported a low-to-moderate impact of weight on self-perception. In preparation for Ramadan, participants sought physician advice on diabetes management (37%) and/or increased checks of their blood glucose (37%). After watching the videos, 89% (n=277) of participants indicated a device preference, with significantly more preferring the dulaglutide device (n=186, 67%) over the semaglutide device (n=91, 33%) (p<0.0001). Conclusion This study indicates that T2DM has a significant social, emotional, and behavioral impact on the lives of patients in KSA.

show abstract

Section: Introductionsupporting

confidence: 73%

<p>Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia</p>

Gelhorn¹,

Boye²,

Shalhoub³

et al. 2020

PPA

View full text Add to dashboard Cite

show abstract

“…Data were from an open-label, multicenter, randomized, crossover study (ClinicalTrials.gov identifier: NCT03724981) [9,10] assessing patient preference for the dulaglutide singleuse pen [11] and the semaglutide single-patient-use pen among injection-naïve patients with T2D [12]. The devices used in the study were those commercially available in the United States.…”

Section: Methodsmentioning

confidence: 99%

“…After being trained to use each device based on device instructions for use (IFU), participants performed all steps of injection preparation and administered mock injections into an injection pad. Further details of the study design, inclusion/exclusion criteria, and methods have been published previously [9].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ)

Boye

Matza

Currie

et al. 2020

J Patient Rep Outcomes

Self Cite

View full text Add to dashboard Cite

Introduction The Diabetes Injection Device Preference Questionnaire (DID-PQ) was designed to assess patient preference between two non-insulin injection devices. In a recent crossover study, people with type 2 diabetes (T2D) completed the DID-PQ after performing mock injections with two non-insulin injection devices. The purpose of the current analysis was to use these data to assess construct validity of the DID-PQ and demonstrate one way to test whether there is a significant preference for one injection device over another. Methods Data were from an open-label, multicenter, randomized, crossover study assessing preference between the dulaglutide and semaglutide injection pens. In addition to the 10-item DID-PQ, people with T2D completed a global item assessing overall preference. DID-PQ responses were compared to the global preference item (percent agreement, Gwet’s AC1, prevalence-adjusted and bias-adjusted Kappa [PABAK]). For each item of the DID-PQ, a two-sided binomial test assessed whether the difference in preference was statistically significant. Results The sample included 310 participants (48.4% female; mean age = 60.0). The DID-PQ had minimal missing data. There was strong concordance (percent agreement > 78%) between the global preference item and all DID-PQ items except item 6, which assesses preference related to needle size (59.7%). The Gwet AC1 and PABAK statistics also indicated strong agreement between the global preference item and all DID-PQ items except item 6. There was a statistically significant difference (p < 0.0001) in preference on every DID-PQ item, with more participants preferring the dulaglutide device. Discussion Patient preference has been recommended as a “major factor driving the choice of medication” in a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Current findings suggest that the DID-PQ may be a useful tool for providing insight into preferences of people with T2D using non-insulin injectable medication.

show abstract

“…Although PROs for patients taking dulaglutide and liraglutide have previously been reported in clinical trials, real-world evidence is limited [11][12][13][14][15][16][17]. We studied the use of these GLMs in a single prospective observational study, thereby addressing the need for additional real-world evidence.…”

Section: Digital Features Introductionmentioning

confidence: 99%

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes

Boye

Sapin²,

García‐Pérez³

et al. 2020

Diabetes Ther

Self Cite

View full text Add to dashboard Cite

Introduction: Although patient-reported outcome (PRO) measures provide important information beyond clinical data, studies that assess the PROs of type 2 diabetes mellitus (T2DM) patients initiating injectable glucose-lowering medications in routine clinical practice are limited. We describe the perspectives of patients based on a diversified panel of generic and disease-specific PRO measures at the time of enrollment (baseline) in the TROPHIES study. Methods: TROPHIES is a 24-month prospective observational study performed in France, Germany, and Italy in patients with T2DM who initiated their first injectable glucose-lowering medication with once-weekly dulaglutide or once-daily liraglutide. To better understand the perspectives of these patients regarding their overall health, treatment satisfaction, and quality of life and work, the patients' responses to the following questionnaires were collected at baseline before they initiated treatment with dulaglutide or liraglutide:

show abstract

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

Cited by 35 publications

References 54 publications

<p>Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia</p>

<p>Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia</p>

Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes

Contact Info

Product

Resources

About